| P50 | author | Electron Kebebew | Q88461842 |
| | Martha Quezado | Q110348734 |
| P2093 | author name string | Lisa Zhang | |
| | Meenu Jain | |
| | Stephanie Barak | |
| | Allison B Weisbrod | |
| P2860 | cites work | PML nuclear bodies | Q22065791 |
| | Cell cycle-dependent phosphorylation of the ATRX protein correlates with changes in nuclear matrix and chromatin association | Q22253267 |
| | The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies | Q24319767 |
| | Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms | Q26853361 |
| | Vascular endothelial growth factor (VEGF) - part 2: in endocrinology and oncology | Q27024965 |
| | ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome | Q27670417 |
| | Regulation of p53 stability by Mdm2 | Q27860744 |
| | The mTOR pathway and its role in human genetic diseases | Q28285976 |
| | Daxx: death or survival protein? | Q28291053 |
| | RNAi-mediated pathways in the nucleus | Q28300961 |
| | DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors | Q28303693 |
| | Heterochromatin and ND10 are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of the transcription repressor Daxx and SWI/SNF protein ATRX | Q28505387 |
| | ATRX partners with cohesin and MeCP2 and contributes to developmental silencing of imprinted genes in the brain | Q28512087 |
| | Essential role for nuclear PTEN in maintaining chromosomal integrity | Q28513781 |
| | PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model | Q32069431 |
| | P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts | Q33933630 |
| | Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas | Q57767637 |
| | Increased expression of mutant forms of p53 oncogene in primary lung cancer | Q58212568 |
| | Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs) | Q58417136 |
| | Exacerbation of protracted-relapsing experimental allergic encephalomyelitis in DA rats by gluten-free diet | Q59487959 |
| | Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors | Q60609612 |
| | Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate | Q71625847 |
| | Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms | Q74250330 |
| | Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies | Q77102007 |
| | Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells | Q78834996 |
| | WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors | Q80146356 |
| | Cleaved caspase-3 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors: A potential marker for biological malignancy | Q82567100 |
| | Von Hippel Lindau syndrome | Q34129844 |
| | Altered telomeres in tumors with ATRX and DAXX mutations | Q34196696 |
| | The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification | Q34321928 |
| | DNA methylation and control of gene expression in vertebrate development | Q34471542 |
| | Assessing TP53 status in human tumours to evaluate clinical outcome | Q34570100 |
| | Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway | Q34887795 |
| | Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation | Q35089377 |
| | Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors | Q35681234 |
| | Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells | Q35745875 |
| | TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. | Q35837124 |
| | The positive regulation of p53 by the tumor suppressor VHL. | Q36592019 |
| | Chromogranins A and B and secretogranin II: evolutionary and functional aspects | Q37001666 |
| | Calcium signalling and cancer cell growth. | Q37056451 |
| | The nuclear affairs of PTEN. | Q37063858 |
| | Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion | Q37142419 |
| | Von Hippel-Lindau (VHL) disease: an update on the clinico-pathologic and genetic aspects | Q37147041 |
| | Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. | Q37270416 |
| | Granins and granin-related peptides in neuroendocrine tumours | Q37704780 |
| | Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease | Q37706151 |
| | The role of PML in the nervous system | Q37821367 |
| | Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy | Q37981893 |
| | Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells | Q38333497 |
| | Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli | Q38488165 |
| | Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. | Q39704965 |
| | PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma | Q39844741 |
| | Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis | Q40372916 |
| | Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis | Q40647696 |
| | Cancer therapy and p53. | Q40938367 |
| | Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport | Q41694667 |
| | Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors | Q43008626 |
| | Loss of PTEN expression in neuroendocrine pancreatic tumors | Q43887224 |
| | A Functional Interaction between Chromogranin B and the Inositol 1,4,5-Trisphosphate Receptor/Ca2+ Channel | Q44594114 |
| | Modulation of Prostate Carcinoma Cell Growth and Apoptosis by Chromogranin A | Q44610279 |
| | Argyrophilia and chromogranin A and B immunostaining in patients with sporadic medullary thyroid carcinoma. A critical appraisal of their prognostic utility | Q47843188 |
| | Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. | Q53437252 |
| | Selective processing of chromogranin A in the different islet cells in human pancreas. | Q53775188 |
| | Daxx is required for stress-induced cell death and JNK activation. | Q53851366 |
| | Infrequent alteration of p53 pathway in metastatic renal cell carcinoma. | Q54105033 |
| | VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma. | Q54627123 |
| | Von Hippel Lindau Syndrome | Q56068021 |
| | Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients | Q57425794 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 165-175 | |
| P577 | publication date | 2013-01-30 | |
| P1433 | published in | Hormones and Cancer | Q15716573 |
| P1476 | title | Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors | |
| P478 | volume | 4 | |